Skip to main content
main-content

12.11.2015 | Onkologie | Onlineartikel

News on targeted agents in the advanced setting

Squamous-cell carcinoma of the lung represents approximately 30 % of non–small-cell lung cancer (NSCLC) cases. Until 2015, docetaxel and erlotinib were the only approved second-line treatment options in these patients. Typically, squamous-cell carcinoma of the lung has a high burden of somatic mutations and genomic alterations. Overexpression and dysregulation of EGFR, FGFR1, PI3K and their downstream pathways are implicated in the pathogenesis, providing a rationale for the use of ErbB inhibitors in this setting of major medical need.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten